Amundi Trims Holdings in Solventum Corporation $SOLV

Amundi trimmed its position in Solventum Corporation (NYSE:SOLV - Free Report) by 21.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 526,437 shares of the company's stock after selling 142,679 shares during the quarter. Amundi owned about 0.30% of Solventum worth $36,951,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Rossby Financial LCC purchased a new position in shares of Solventum in the first quarter worth about $25,000. Strengthening Families & Communities LLC raised its stake in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Solventum in the fourth quarter worth about $29,000. Colonial Trust Co SC raised its stake in shares of Solventum by 240.7% in the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company's stock worth $34,000 after purchasing an additional 361 shares during the last quarter. Finally, Hara Capital LLC purchased a new position in shares of Solventum in the first quarter worth about $38,000.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. KeyCorp assumed coverage on Solventum in a report on Friday, June 6th. They set a "sector weight" rating on the stock. Morgan Stanley raised Solventum from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Wall Street Zen lowered Solventum from a "strong-buy" rating to a "buy" rating in a report on Tuesday. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $85.75.

Solventum Price Performance

SOLV traded down $1.66 during trading on Tuesday, hitting $72.94. The company's stock had a trading volume of 930,094 shares, compared to its average volume of 1,280,160. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The business's fifty day simple moving average is $73.40 and its 200 day simple moving average is $72.76. The firm has a market capitalization of $12.65 billion, a price-to-earnings ratio of 33.77, a P/E/G ratio of 3.05 and a beta of 0.53.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.